IDEAYA Biosciences Reveals Late-Breaking Abstract Oral Presentation At ASCO 2026 To Provide Complete Data from Phase 2/3 Registrational Trial Of Darovasertib In Combination With Crizotinib In 1L HLA*A2-Negative Metastatic Uveal Melanoma
Benzinga Newsdesk 6 months ago
BiotechNewsGeneral
- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, today announced they have been selected for a late-breaking abstract (LBA) oral presentation to provide the complete data from the
- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, today announced they have been selected for a late-breaking abstract (LBA) oral presentation to provide the complete data from the Phase 2/3 registrational trial (OptimUM-02) of darovasertib in combination with crizotinib in first-line (1L) HLA*A2-negative metastatic uveal melanoma at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on May 29-June 2 in Chicago, Illinois. The presentation will include detail and additional data from OptimUM-02 that were not disclosed with the company's topline release.